Koji Nagafuji
About
Koji Nagafuji is a scholar working on Hematology, Oncology and Immunology.
According to data from OpenAlex, Koji Nagafuji has authored 181 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 95 papers in Hematology, 55 papers in Oncology and 46 papers in Immunology. Recurrent topics in Koji Nagafuji's work include Hematopoietic Stem Cell Transplantation (58 papers), Lymphoma Diagnosis and Treatment (28 papers) and Acute Myeloid Leukemia Research (27 papers). Koji Nagafuji is often cited by papers focused on Hematopoietic Stem Cell Transplantation (58 papers), Lymphoma Diagnosis and Treatment (28 papers) and Acute Myeloid Leukemia Research (27 papers). Koji Nagafuji collaborates with scholars based in Japan, United States and South Korea. Koji Nagafuji's co-authors include Toshihiro Miyamoto, Koichi Akashi, Mine Harada, Katsuto Takenaka, Hisashi Gondo, Takashi Okamura, Takanori Teshima, Hiromi Iwasaki, Goichi Yoshimoto and Tetsuya Eto and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and Blood.
In The Last Decade
Koji Nagafuji
166 papers receiving 3.9k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Koji Nagafuji Japan | 33 | 1.6k | 1.4k | 1.2k | 845 | 780 | 181 | 4.0k | ||
| Junichi Hara Japan | 34 | 1.1k 0.7× | 1.0k 0.7× | 996 0.8× | 535 0.6× | 602 0.8× | 177 | 4.1k | ||
| Wolfgang Bethge Germany | 35 | 1.9k 1.2× | 1.3k 0.9× | 1.3k 1.1× | 373 0.4× | 776 1.0× | 193 | 3.9k | ||
| Fiona E. Craig United States | 29 | 801 0.5× | 1.4k 1.0× | 1.2k 1.0× | 1.4k 1.6× | 666 0.9× | 104 | 4.0k | ||
| Kirsty Thomson United Kingdom | 34 | 1.5k 0.9× | 1.4k 1.0× | 986 0.8× | 1.2k 1.4× | 595 0.8× | 91 | 3.3k | ||
| Keisei Kawa Japan | 35 | 1.8k 1.1× | 2.1k 1.5× | 1.8k 1.5× | 1.2k 1.5× | 490 0.6× | 109 | 4.6k | ||
| Hendrik Veelken Germany | 38 | 1.3k 0.8× | 1.6k 1.1× | 2.4k 2.0× | 1.4k 1.6× | 556 0.7× | 181 | 5.6k | ||
| Hisashi Gondo Japan | 29 | 1.5k 0.9× | 792 0.6× | 1.1k 0.9× | 317 0.4× | 542 0.7× | 79 | 2.9k | ||
| Hugo Castro‐Malaspina United States | 36 | 3.3k 2.0× | 1.7k 1.2× | 1.9k 1.6× | 662 0.8× | 940 1.2× | 153 | 5.1k | ||
| Giuseppe Torelli Italy | 42 | 1.1k 0.7× | 2.2k 1.5× | 620 0.5× | 786 0.9× | 1.5k 1.9× | 172 | 4.9k | ||
| F Sigaux France | 28 | 890 0.6× | 2.2k 1.6× | 876 0.7× | 953 1.1× | 1.1k 1.4× | 69 | 4.0k |
Countries citing papers authored by Koji Nagafuji
Since
Specialization
Citations
This map shows the geographic impact of Koji Nagafuji's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Koji Nagafuji with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Koji Nagafuji more than expected).
Fields of papers citing papers by Koji Nagafuji
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Koji Nagafuji. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Koji Nagafuji. The network helps show where Koji Nagafuji may publish in the future.
Co-authorship network of co-authors of Koji Nagafuji
This figure shows the co-authorship network connecting the top 25 collaborators of Koji Nagafuji. A scholar is included among the top collaborators of Koji Nagafuji based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Koji Nagafuji. Koji Nagafuji is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Kato, Koji, Hideki Nakasone, Nobuaki Nakano, et al.. (2025). Low Survival Due to Higher Risk of Relapse and Nonrelapse Mortality After Allogeneic HSCT in ATL Compared with AML and ALL. Transplantation and Cellular Therapy. 31(4). 253.e1–253.e14.
2.
Lee, Jong Wook, Jun Ho Jang, Hirohito Yamazaki, et al.. (2025). Addition of romiplostim to immunosuppressive therapy as first-line treatment for patients with aplastic anemia. Blood Advances. 9(22). 5732–5735.
3.
Ozawa, Hidetoshi, et al.. (2024). High-dose cytarabine plus gemtuzumab ozogamicin as consolidation therapy in patients with favorable- or intermediate-risk acute myeloid leukemia. International Journal of Hematology. 120(3). 297–304.
4.
Sugio, Takeshi, Naoyuki Uchida, Kohta Miyawaki, et al.. (2024). Prognostic impact of HLA supertype mismatch in single-unit cord blood transplantation. Bone Marrow Transplantation. 59(4). 466–472.
5.
Mori, Yasuo, Jun Takizawa, Naoki Takezako, et al.. (2024). Autologous HSCT with novel agent‐based induction and consolidation followed by lenalidomide maintenance for untreated multiple myeloma. Cancer Science. 115(6). 2002–2011.
6.
Nakamae, Hirohisa, Eisei Kondo, Takahiro Fukuda, et al.. (2024). Peripheral blood stem cell transplantation using HLA-haploidentical donor with post-transplant cyclophosphamide versus HLA-matched sibling donor for lymphoma. Bone Marrow Transplantation. 59(5). 630–636.
7.
Onozawa, Masahiro, Shigeru Kusumoto, Yuho Najima, et al.. (2024). Outcomes of Cessation of Nucleos(t)ide Analog Administration on Hepatitis B Virus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation: A Nationwide Retrospective Study. Transplantation and Cellular Therapy. 30(3). 330.e1–330.e8.
8.
Fuji, Shigeo, Junichi Sugita, Yuho Najima, et al.. (2023). Low‐ versus standard‐dose post‐transplant cyclophosphamide as GVHD prophylaxis for haploidentical transplantation. British Journal of Haematology. 204(3). 959–966.
9.
Shimomura, Yoshimitsu, Sho Komukai, Tetsuhisa Kitamura, et al.. (2023). Effect of graft-versus-host disease on outcomes of HLA-haploidentical peripheral blood transplantation using post-transplant cyclophophamide. Bone Marrow Transplantation. 59(1). 66–75.
10.
Miyamoto, Toshihiro, Tetsuya Eto, Naoyuki Uchida, et al.. (2021). Clinical features and chromosomal/genetic aberration in adult acute lymphoblastic leukemia in Japan: results of Fukuoka Blood & Marrow Transplant Group Studies ALL MRD 2002 and 2008. International Journal of Hematology. 113(6). 815–822.
11.
Ozawa, Hidetoshi, Kensuke Sasaki, Yuichiro Semba, et al.. (2020). Beneficial tyrosine kinase inhibitor therapy in a patient with relapsed BCR-ABL1-like acute lymphoblastic leukemia with CCDC88C-PDGFRB fusion. International Journal of Hematology. 113(2). 285–289.
12.
Nakamura, Takayuki, Hidetoshi Ozawa, Maki Yamaguchi, et al.. (2020). Successful correction of factor V deficiency of patient‐derived iPSCs by CRISPR/Cas9‐mediated gene editing. Haemophilia. 26(5). 826–833.
13.
Nagafuji, Koji, Itaru Matsumura, Takayuki Shimose, et al.. (2019). Cessation of nilotinib in patients with chronic myelogenous leukemia who have maintained deep molecular responses for 2 years: a multicenter phase 2 trial, stop nilotinib (NILSt). International Journal of Hematology. 110(6). 675–682.
14.
Nagafuji, Koji, Toshihiro Miyamoto, Tetsuya Eto, et al.. (2019). Prospective evaluation of minimal residual disease monitoring to predict prognosis of adult patients with Ph‐negative acute lymphoblastic leukemia. European Journal Of Haematology. 103(3). 164–171.
15.
Mizuno, Shinichi, Hidetoshi Ozawa, Takayuki Nakamura, et al.. (2019). CRISPR/Cas9-mediated gene correction in hemophilia B patient-derived iPSCs. International Journal of Hematology. 111(2). 225–233.
16.
Kawamoto, Keisuke, Hiroaki Miyoshi, Eriko Yanagida, et al.. (2017). Comparison of clinicopathological characteristics between T‐cell prolymphocytic leukemia and peripheral T‐cell lymphoma, not otherwise specified. European Journal Of Haematology. 98(5). 459–466.
17.
Yoshimoto, Goichi, Toshihiro Miyamoto, Siamak Jabbarzadeh‐Tabrizi, et al.. (2009). FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD–specific STAT5 activation. Blood. 114(24). 5034–5043.
18.
Kikushige, Yoshikane, Ken Takase, Toshihiro Miyamoto, et al.. (2006). Late Relapse of Acute Myelogenous Leukemia Followed by Epstein-Barr Virus-Associated Lymphoproliferative Disease 11 Years after Allogeneic Bone Marrow Transplantation. International Journal of Hematology. 84(5). 441–444.
19.
Harada, Mine, Koji Nagafuji, Tomoaki Fujisaki, et al.. (1996). G-CSF-Induced Mobilization of Peripheral Blood Stem Cells from Healthy Adults for Allogeneic Transplantation. Journal of Hematotherapy. 5(1). 63–71.
20.
Nagafuji, Koji & Mine Harada. (1995). Autologous Blood Stem Cell Transplantation-Current Status and Issues-. 36(6). 530–537.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Junichi Hara Breakdown of academic impact, for papers by Wolfgang Bethge Breakdown of academic impact, for papers by Fiona E. Craig Breakdown of academic impact, for papers by Kirsty Thomson Breakdown of academic impact, for papers by Keisei Kawa Breakdown of academic impact, for papers by Hendrik Veelken Breakdown of academic impact, for papers by Hisashi Gondo Breakdown of academic impact, for papers by Hugo Castro‐Malaspina Breakdown of academic impact, for papers by Giuseppe Torelli Breakdown of academic impact, for papers by F Sigaux